Related Experiment Videos
Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study
L Widmer1, L Biland, J P Barras
1Department of Medicine, Basel University Hospital, Switzerland.
Summary
Doxium significantly improved symptoms of chronic venous insufficiency (CVI) compared to placebo. Patients taking Doxium experienced reduced leg edema, pain, and cramps, demonstrating its therapeutic efficacy.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Chronic venous insufficiency (CVI) is a prevalent condition affecting leg circulation.
- Effective management of CVI symptoms like edema and pain remains a clinical challenge.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Doxium in patients with CVI.
- To compare Doxium's effectiveness against a placebo in a double-blind, controlled trial.
Main Methods:
- A 4-week, double-blind, placebo-controlled study involving 225 CVI patients.
- Patients received either Doxium (1.5 g/day) or placebo.
- Leg edema measured by circumference; pain and discomfort assessed using visual analogue scales.
Main Results:
- Doxium significantly reduced leg edema (3.8% vs 1.2% for placebo, p<0.005).
- Marked improvements observed in pain, cramps, discomfort, heavy legs, paresthesia, and restless legs with Doxium.
- Physician assessment showed 82% improvement in Doxium group vs 42% in placebo group (p<0.0001).
Conclusions:
- Doxium demonstrates significant therapeutic efficacy in managing chronic venous insufficiency.
- The treatment is well-tolerated, with comparable safety to placebo.
- Doxium offers a valuable therapeutic option for CVI patients experiencing edema and associated symptoms.